Articles tagged with T Cell Lymphoma
A new study reveals that mature B cells temporarily gain plasticity during the antibody-making process, which could explain how many lymphomas develop from mature B cells. Researchers discovered that this epigenetic change is tightly regulated and can be hijacked by specific mutations to promote lymphomagenesis.
Researchers at Johns Hopkins Kimmel Cancer Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, preserving approximately 40%–60% of normal T cells. The therapy, an antibody-drug conjugate, provides a long-sought therapeutic option for half of T-cell lymphomas and leukemias.
A global study found that patients with mature nodal T-cell lymphoma who relapsed within 12 months of initial treatment had worse survival outcomes, but improved survival when treated with targeted therapies instead of chemotherapy. The results suggest the need for personalized treatment strategies for high-risk patients.
Researchers from the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center will present their work on various hematological conditions at ASH 2025. These posters highlight recent findings in fields such as von Willebrand disease, multiple myeloma, and acute myeloid leukemia.
VCU Massey Comprehensive Cancer Center is the first US site to enroll patients in a global Phase 2a clinical trial of PTX-100, a small molecule inhibitor for cutaneous T-cell lymphoma. The trial aims to evaluate the efficacy and safety of PTX-100 in patients with relapsed or refractory disease.
Researchers at Mass General Brigham found a novel strategy to help patients control their disease, increasing eligibility for stem cell transplants. The combination of duvelisib and romidepsin was effective, tolerable, and safe for patients with relapsed/refractory peripheral and cutaneous T-cell lymphomas.
This study identifies three molecular classifications of T-follicular helper lymphoma based on genetic mutations, including C1, C2, and C3, which show different prognostic outcomes. The research also classifies tumor microenvironments into three types, with TME2 linked to poor outcomes.
A new CAR-T therapy, HSP-CAR30, has achieved positive results in a high proportion of patients with refractory CD30+ lymphoma. The treatment promotes the expansion of memory T cells, leading to durable responses and improved clinical outcomes.
A Phase I clinical trial reveals that HSP-CAR30 CAR-T cell therapy promotes the expansion of memory T cells, leading to long-lasting responses and improved clinical outcomes in treated patients. The treatment exhibits a favorable safety profile, with no dose-limiting toxicities detected.
Castleman disease is a rare lymphoproliferative disorder with overlapping features with reactive and neoplastic diseases. The condition is characterized by vascularized regressed follicles and fibrotic stroma, and diagnosis relies on a combination of clinical, laboratory, and histological findings.
A rare case of T cell lymphoma developed in a patient with multiple myeloma nine months after CAR-T cell therapy. Genetic alterations in the patient's haematopoietic cells played a role in tumour development, highlighting the importance of genetic predispositions for potential side effects.
Researchers found that EZH2 inhibition boosts T-cell immunotherapies' effectiveness by making cancer cells more visible and reducing immunosuppressive regulatory T-cells. This combination therapy showed improved survival rates in mice with lymphomas, suggesting a potential new approach to treating certain cancers.
More than 70 hematology researchers from the University of Miami Miller School of Medicine will showcase their work at the 66th ASH Annual Meeting & Exposition. Researchers from Sylvester Comprehensive Cancer Center are authors or co-authors on a significant number of posters presented during the event.
A preclinical study suggests that knocking out CD5 on CAR T cells boosts their anti-tumor efficacy against various cancers, including solid tumors. The researchers found that CD5 deletion enhances the function of CAR T cells by reining in immune responses and increasing cancer-cell-killing activity.
Researchers identified a small set of proteins governing anaplastic large cell lymphoma (ALCL) identity and found that drugs targeting the STAT family of proteins already exist for treatment. The study provides insight into potential vulnerabilities in ALCL cells.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
Researchers at Penn Medicine analyzed over 400 patients treated with CAR T cell therapy and found only 16 cases of second cancers, mostly solid tumors. A single case of CAR-negative T-cell lymphoma was identified in a patient who developed a secondary lung tumor after treatment.
Researchers have decoded the factor driving rapid growth of T cell lymphomas, revealing a 'sugar appetite' that triggers processes leading to tumor growth. The discovery provides new hope for treating aggressive cancer types, with existing medications potentially effective against these tumors.
Studies at single-cell resolution reveal significant tumor cell heterogeneity and an immune-evasive environment that contributes to treatment resistance in T follicular helper cell lymphomas. A novel marker, PLS3, is also identified as a key player in this process.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
Patients with inflammatory bowel disease (IBD) are at a higher risk of developing lymphoma, particularly those with Crohn's disease. The risk is driven by both the disease activity and treatment, including immunomodulating drugs.
Researchers have discovered a new biomarker that predicts the response to CAR-T cell therapy in patients with diffuse large B cell lymphoma. The biomarker identifies differentiated T cells, which can be removed from leukemia products to improve therapy success rates.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
A University of Houston engineer has developed technology to determine which patients are likely to respond to CAR T-cell therapy for lymphoma, saving time and increasing success rates. The TIMING method analyzes interactions between T cells and tumor cells, identifying a key ligand molecule that predicts patient response.
A new peptide-based vaccine, CoVac-1, has been shown to induce a T cell-dependent response in 93% of patients with B-cell deficiencies, including those with leukemia and lymphoma. The vaccine's T cell immunity exceeds that of individuals without immune deficiency or those who have received standard COVID-19 vaccines.
A CHOP-led study found bortezomib significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma. The trial also showed that intensifying the chemotherapy regimen allowed for elimination of radiation in nearly all patients, resulting in excellent outcomes.
Moffitt researchers have identified key genomic alterations and potential therapeutic targets in transformed cutaneous T-cell lymphoma. The study, which analyzed 56 patient samples, found high tumor mutation burden and UV mutation signatures associated with survival outcomes. The research also uncovered novel therapeutic vulnerabilitie...
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
A team of scientists from the University of Pittsburgh and National Cancer Institute discovered why HIV is rarely the direct cause of cancer. The research found that it requires a specific series of events involving changes in HIV and additional mutations in human genes, resulting in T cell lymphomas. However, the occurrence is rare, a...
A genetic analysis reveals that a rare type of blood cancer affecting immune T cells may be caused by exposure to smoking and aging-related mutations in blood precursor cells. The study found a potential link between the development of these tumours and second-hand smoke, suggesting cessation may prevent their occurrence.
A new study suggests that T cell therapy alone or combined with cancer drug nivolumab is safe and persistent in attacking Hodgkin's lymphoma cells. The treatment showed promising results in patients with relapsed or refractory HL, offering a potential option for those who do not respond to checkpoint inhibitors.
Researchers have developed a new chimeric antigen receptor (CAR) T cell immunotherapy that targets both CD19 and CD20 proteins, achieving complete metabolic responses in four out of five patients with relapsed or refractory B-cell lymphoma. The approach minimizes treatment resistance and prevents relapse by recognizing multiple targets.
A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times. Nearly three-quarters of the patients had at least a partial response to the therapy, with about a third achieving complete remission.
Researchers successfully targeted Cryptococcus species using reprogrammed CAR T-cells, effectively controlling the growth of fungi. The treatment showed promising results in vitro and in mice, with reduced titan cells indicating a good prognosis for new treatments. This innovative approach could also be applied to other fungal infections.
A significant number of NHL patients achieved complete remission and progression-free survival with Kymriah, a personalized cellular therapy. The study demonstrated the durability of this approach, with most patients remaining in remission five years after treatment.
Research at H. Lee Moffitt Cancer Center & Research Institute identified immune dysregulation as a key factor hindering CAR T-cell expansion and effectiveness in diffuse large B-cell lymphoma patients. The study suggests that addressing underlying immune characteristics may improve treatment outcomes.
Researchers have found that knocking out the CD5 gene on CAR T cells using CRISPR-Cas9 technology enhances their ability to eliminate blood cancers. Mice infused with CD5-deleted CAR T cells showed higher T cell proliferation and reduced tumor size compared to non-edited cells.
Axicabtagene ciloleucel (axi-cel) achieved undetectable cancer levels in nearly 80% of patients, and durable responses in most participants. The therapy demonstrated improved response rates for follicular lymphoma compared to marginal zone lymphoma.
Researchers at the University of Tsukuba have discovered how VAV1 gene mutations can promote the development of T-cell tumors in laboratory mice. The study found that mice with both VAV1 mutations and lack of p53 developed mature tumors resembling human peripheral T-cell lymphoma.
Researchers have identified cathepsin S as a key player in Non-Hodgkin lymphoma's ability to evade the immune system. Inhibiting this protein reduces tumor growth by increasing the activity of immune cells that kill cancer cells.
A Phase II study found that 93% of patients with relapsed or refractory mantle cell lymphoma responded to CD19-targeting CAR T-cell therapy KTE-X19, with 67% achieving a complete response. The estimated progression-free survival and overall survival were 61% and 83%, respectively.
Adult lymphoma patients treated with CAR-T therapy reported improved physical and social function, as well as better emotional and mental health. The study suggests that CAR-T may not only extend survival but also improve quality of life after treatment.
Researchers have discovered ways to boost CAR T-cell therapy, surveying over 500 cancer drugs on its function. SMAC mimetics sensitize cancer cells to CAR T cells, while inhibiting CAR T cell functions could treat adverse effects.
Researchers at City of Hope have developed a new CAR T cell therapy targeting the B cell-activating factor receptor (BAFF-R), which showed remarkable tumor regression and prolonged survival in animal models. The therapy may potentially be used as a first-line treatment for patients who relapsed after CD19 immunotherapy treatments.
Researchers at MUSC discovered that thioredoxin, a powerful antioxidant molecule, can extend the life of adoptive T-cells and improve anti-tumor activity. This finding suggests that treating human T-cells with thioredoxin before administration may increase cell viability and improve the effectiveness of immune-based therapies.
Researchers at Helmholtz Zentrum München have developed a novel T-cell therapy that can eliminate hepatitis B viruses from the liver, paving the way for a potential cure. The therapy involves genetically modifying patient-specific T cells to recognize and attack infected liver cells, with promising results in a mouse model.
A study by Brigham and Women's Hospital found that 77% of patients experienced at least one neurological symptom after CAR-T treatment, which were often temporary. The symptoms included encephalopathy, headache, tremor, weakness, and language dysfunction, with most effects being reversible.
A new CAR molecule has been developed that kills cancer cells with less toxicity, allowing for remissions without serious side effects. Researchers have produced no severe side effects in patients with lymphoma, showing promise for a safer version of the therapy
CAR T cells kill cancer cells directly, rather than relying on other immune cells. Reducing encounters with circulating B cells can enhance CAR T cell infiltration and persistence, improving treatment outcomes.
A Mayo Clinic study found that patients with a poor immune response to follicular lymphoma exhibited reduced costimulatory receptors on their T-cells, leading to shorter survival rates. The research may lead to the development of new therapies for some patients with follicular lymphoma.
The SU2C Meg Vosburg T-Cell Lymphoma Dream Team is developing CAR-based immunotherapy strategies to target cancerous T cells without harming the immune system. The team aims to find a therapy that can improve outcomes in this patient population and make treatments more available.
The Blood editors have selected the top 10 manuscripts of 2018, showcasing notable advances in various hematological disorders. These studies highlight promising treatments for B-cell precursor acute lymphoblastic leukemia and classical Hodgkin lymphoma, as well as novel therapeutic strategies for immune thrombocytopenia.
Researchers reported promising early results from a clinical study of genetically engineered immune cells that recognize and fight cancer cells. The treatment generated excellent responses when used after chemotherapy, with 71% of patients achieving complete response.
Navin Varadarajan is modifying T cells to recognize and kill glypican-3, a molecule found in liver cancer cells. The goal is to develop an effective treatment for high-risk pediatric liver cancer with poor survival rates.
A PLOS Neglected Tropical Diseases study finds that 7.3% of Gabonese adults and teens are infected with HTLV-1, a risk factor for adult T-cell lymphoma and other diseases. The study calls for nationwide sexual health programs, blood donor screening, and pregnant woman education to combat transmission.
Research suggests an inverse relationship between fever and cancer incidence, potentially linked to enhanced gamma/delta T cell activity. This mechanistic hypothesis proposes that repeated exposure to fever boosts the ability of these T cells to detect cellular abnormalities and destroy malignant cells.
A new tool uses high-throughput DNA sequencing to accurately predict which early-stage Cutaneous T Cell Lymphoma (CTCL) patients are at risk of developing an aggressive form of the disease. The tool, which analyzes specific genes, has shown promise in improving treatment outcomes for these patients.
Researchers at Children's National Hospital have developed T-cells that can resist tumor-induced immune suppression, leading to sustained clinical responses in patients with relapsed Hodgkin lymphoma. The study shows promise for treating other types of immune-evading tumors.
Researchers at Harvard's Wyss Institute have developed an immune-mimicking biomaterial that can amplify patient-specific T cells outside the body, increasing efficiency of cancer immunotherapies. The new approach mimics the process by which antigen-presenting cells stimulate T cells to expand and stay alive.